Outlook Therapeutics, Inc.
Price Action
Technical Summary
CONSOLIDATINGOutlook Therapeutics, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is leading (RS Rating: 98), indicating clear outperformance against the broad market. Earnings growth of 96% provides fundamental context to the price action. However, price is extended 161% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $1.19 | +43.34% | ABOVE |
| 50 SMA | $0.66 | +160.91% | ABOVE |
| 100 SMA | $0.50 | +239.56% | ABOVE |
| 150 SMA | $0.78 | +117.86% | ABOVE |
| 200 SMA | $0.89 | +91.13% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is OTLK in an uptrend right now?
OTLK has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is OTLK overbought or oversold?
OTLK's RSI (14) is 73. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is OTLK outperforming the market?
OTLK has a Relative Strength (RS) Rating of 98 out of 99. Yes, OTLK is a market leader, outperforming 98% of all stocks over the past 12 months.
Where is OTLK in its 52-week range?
OTLK is trading at $1.71, which is 50% of its 52-week high ($3.39) and 48% above its 52-week low ($0.16).
How volatile is OTLK?
OTLK has a Beta of 1.25 and 52-week volatility of 158%. It's more volatile than the S&P 500 - expect bigger swings.